GlassScriptPhysician profile
Carlos A Tejeda
NPI 1851342703
$9,752.03
in general payments reported to CMS, 2019-2025
55 companies · $847 in 2025
The $847 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,835 · 2020: $1,044 · 2021: $1,695 · 2022: $1,706 · 2023: $1,180 · 2024: $1,445 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,781.26 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $872.30 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $781.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $781.32 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $462.09 | 2020-2022 | |
| Pfizer INC. | $389.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $347.07 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $313.79 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $282.35 | 2019-2024 | |
| Lilly USA, LLC | $269.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $269.67 | 2019-2022 | |
| Glaxosmithkline, LLC. | $261.81 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $260.27 | 2021-2022 | |
| Amarin Pharma, INC. | $227.77 | 2019-2022 | |
| Abiomed | $212.61 | 2021-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Tejeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.